The guinea pig (gp) model of congenital cytomegalovirus (CMV) infection was used to evaluate a gpCMV glycoprotein vaccine. Hartley guinea pigs were immunized 3 times with 50 μg of lectin column-purified glycoproteins prepared from gpCMV-infected or -uninfected tissue culture. Immunization with the gpCMV vaccine produced seroconversion in all animals. Animals then were placed with gpCMV-seronegative male animals and were challenged late in pregnancy with virulent salivary gland-passaged gpCMV. Immunization with gpCMV glycoproteins significantly improved pregnancy outcome, with 54 of 63 pups live-born in immunized animals, compared with 21 of 48 in the controls (P < .001). In addition, virus was isolated from 24 of 54 live-born pups born to immunized mothers, compared with 16 of 20 live-born pups born to controls, indicating that immunization significantly reduced in utero transmission in surviving animals (P < .01).
Bibliographical noteFunding Information:
Received 30 June 2000; revised 11 September 2000; electronically published 21 November 2000. Presented in part: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 15–18 September 1996 (abstract H87). Animal studies were approved by the Children’s Hospital Medical Center Animal Care and Use Committee. Financial support: National Institutes of Health (contract AI-65289); March of Dimes Birth Defects Foundation (grant FY98-0416); SmithKline Beecham Biologicals, Rixensart, Belgium. Reprints or correspondence: Dr. Nigel Bourne, Division of Infectious Diseases, Children’s Hospital Medical Center, 3333 Burnet Ave., Cincinnati, Ohio 45229 (firstname.lastname@example.org).